ARTV
Income statement / Annual
Last year (2025), Artiva Biotherapeutics Inc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Artiva Biotherapeutics Inc's net income was -$83.87 M.
See Artiva Biotherapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$251.00 K |
$33.49 M |
$4.93 M |
$2.00 M |
$0.00 |
| Cost of Revenue |
$2.60 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$2.60 M
|
$251.00 K
|
$33.49 M
|
$4.93 M
|
$2.00 M
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$69.54 M
|
$50.33 M
|
$50.25 M
|
$43.98 M
|
$42.41 M
|
$13.85 M
|
| General & Administrative Expenses |
$20.27 M
|
$17.21 M
|
$13.91 M
|
$20.78 M
|
$12.86 M
|
$4.43 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.27 M
|
$17.21 M
|
$13.91 M
|
$20.78 M
|
$12.86 M
|
$4.43 M
|
| Other Expenses |
-$1.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$88.01 M
|
$67.53 M
|
$64.16 M
|
$64.76 M
|
$55.27 M
|
$18.27 M
|
| Cost And Expenses |
$90.61 M
|
$67.53 M
|
$64.16 M
|
$64.76 M
|
$55.27 M
|
$18.27 M
|
| Interest Income |
$5.96 M
|
$5.35 M
|
$2.54 M
|
$1.29 M
|
$0.00
|
$2.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$199.00 K
|
| Depreciation & Amortization |
$2.60 M
|
$2.43 M
|
$2.27 M
|
$1.16 M
|
$248.00 K
|
$73.00 K
|
| EBITDA |
-$88.01 M |
-$64.85 M |
-$28.41 M |
-$58.67 M |
-$71.58 M |
-$17.52 M |
| EBITDA Ratio |
0
|
-258.37
|
-0.85
|
-11.9
|
-35.75
|
0
|
| Operating Income Ratio |
0
|
-268.06
|
-0.92
|
-12.13
|
-26.61
|
0
|
| Total Other Income/Expenses Net |
$6.75 M
|
$8.79 M
|
$3.05 M
|
$1.49 M
|
-$18.55 M
|
$280.00 K
|
| Income Before Tax |
-$83.87 M
|
-$58.49 M
|
-$27.62 M
|
-$58.34 M
|
-$71.83 M
|
-$17.99 M
|
| Income Before Tax Ratio |
0
|
-233.04
|
-0.82
|
-11.83
|
-35.88
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$72.00 K
|
$53.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$83.87 M
|
-$58.49 M
|
-$27.70 M
|
-$58.39 M
|
-$71.83 M
|
-$17.99 M
|
| Net Income Ratio |
0
|
-233.04
|
-0.83
|
-11.84
|
-35.88
|
0
|
| EPS |
-3.43 |
-5.2 |
-1.19 |
-3.32 |
-4.08 |
-1.02 |
| EPS Diluted |
-3.43 |
-5.2 |
-1.19 |
-3.32 |
-4.08 |
-1.02 |
| Weighted Average Shares Out |
$24.44 M
|
$24.36 M
|
$23.28 M
|
$17.58 M
|
$17.58 M
|
$17.58 M
|
| Weighted Average Shares Out Diluted |
$24.44 M
|
$24.36 M
|
$23.28 M
|
$17.58 M
|
$17.58 M
|
$17.58 M
|
| Link |
|
|
|
|
|
|
